Related Experiment Video
Updated: Feb 14, 2026

Isolation of Mouse Peritoneal Cavity Cells
Published on: January 28, 2010
Current Management and Future Opportunities for Peritoneal Metastases: Peritoneal Mesothelioma
H Richard Alexander1, Claire Yue Li2, Timothy J Kennedy2
1The Rutgers Cancer Institute of New Jersey and the Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. hrichardalexander@gmail.com.
Purpose:
Diffuse malignant peritoneal mesothelioma (MPM) is a rare and ultimately fatal cancer that was first described just over a century ago. It is a diffuse malignancy arising from the mesothelial lining of the peritoneum; morbidity and mortality from MPM is due to its propensity to progress locoregionally within the abdominal cavity.
Methods:
The purpose of this article is to review the current state-of-the-science related to the diagnosis, staging, and treatment of MPM.
Results:
The condition afflicts men and women equally and the peak incidence is between 55 and 60 years of age although it can arise in the young and elderly. Patients afflicted with MPM most commonly present with nonspecific abdominal symptoms that usually lead to diagnosis when the condition is relatively advanced. Historically, median overall survival for MPM patients without treatment is < 1 year. The couplet of systemic pemetrexed and cisplatin has an overall response rate of approximately 25% and a median overall survival of approximately 1 year.
Conclusion:
The available data, almost all retrospective in nature, have shown that in selected patients, operative cytoreduction (CRS) and regional chemotherapy administered as hyperthermic intraoperative peritoneal chemotherapy (HIPEC) or early postoperative intraperitoneal chemotherapy (EPIC) is associated with long-term survival. Studies on the molecular biology of MPM have yielded new insights relating to the potentially important role of the phosphoinsitide-3-kinase/mammalian target of rapamycin (PI3 K/mTOR) pathways and immune checkpoint inhibitors that may translate into new therapeutic options for patients with diffuse MPM.
Insights
Malignant peritoneal mesothelioma (MPM) is a rare cancer. Surgical cytoreduction with hyperthermic intraoperative peritoneal chemotherapy (HIPEC) offers long-term survival for select patients, with new molecular targets emerging.
Area of Science:
- Oncology
- Surgical Oncology
- Medical Oncology
Background:
- Malignant peritoneal mesothelioma (MPM) is a rare, fatal cancer originating from the peritoneum.
- It progresses locoregionally within the abdominal cavity, leading to significant morbidity and mortality.
- Patients often present with nonspecific symptoms, resulting in late-stage diagnosis.
Purpose of the Study:
- To review the current scientific understanding of MPM diagnosis, staging, and treatment.
- To provide an overview of the state-of-the-science for MPM.
Main Methods:
- Review of retrospective data on MPM diagnosis, staging, and treatment.
- Analysis of current therapeutic strategies including systemic chemotherapy and surgical interventions.
- Exploration of emerging molecular targets and immunotherapies.
Main Results:
- MPM affects men and women equally, typically between ages 55-60.
- Untreated MPM has a median survival of less than 1 year.
- Systemic pemetrexed and cisplatin yield a 25% response rate and 1-year median survival.
Conclusions:
- Operative cytoreduction (CRS) combined with hyperthermic intraoperative peritoneal chemotherapy (HIPEC) or early postoperative intraperitoneal chemotherapy (EPIC) is linked to long-term survival in selected MPM patients.
- Emerging research highlights the role of PI3K/mTOR pathways and immune checkpoint inhibitors.
- These molecular insights may lead to novel therapeutic options for diffuse MPM.
Related Concept Videos
Peritoneal Dialysis III: Nursing Management
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Peritoneal Dialysis I: Introduction and Procedure
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
Electrical Current
Current Density

